John Shaughnessy
Overview
Explore the profile of John Shaughnessy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu-Monette Z, Li Y, Snyder T, Yu T, Lu T, Tzankov A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4808-4821.
PMID: 37728879
Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma...
2.
Dossani R, Shaughnessy J, Kalakoti P, Nanda A
J Neurosurg
. 2017 May;
128(3):938-941.
PMID: 28548597
William Edward Gallie (1882-1959) was a Canadian general surgeon with special expertise in orthopedic surgery. His experience with surgical management of cervical spine subluxation led him to invent a method...
3.
Bam R, Ling W, Khan S, Pennisi A, Upparahalli Venkateshaiah S, Li X, et al.
Am J Hematol
. 2013 Mar;
88(6):463-71.
PMID: 23456977
Myeloma cells typically grow in bone, recruit osteoclast precursors and induce their differentiation and activity in areas adjacent to tumor foci. Bruton's tyrosine kinase (BTK), of the TEC family, is...
4.
Munshi N, Anderson K, Bergsagel P, Shaughnessy J, Palumbo A, Durie B, et al.
Blood
. 2011 Feb;
117(18):4696-700.
PMID: 21292777
A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy...
5.
Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar S, Stewart A, et al.
Mayo Clin Proc
. 2010 Feb;
85(2):197-9.
PMID: 20118399
No abstract available.
6.
Sawyer J, Tian E, Thomas E, Koller M, Stangeby C, Sammartino G, et al.
Br J Haematol
. 2009 Sep;
147(4):484-94.
PMID: 19744130
Gene amplification is defined as a copy number (CN) increase in a restricted region of a chromosome arm, and is a mechanism for acquired drug resistance and oncogene activation. In...
7.
Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, et al.
Best Pract Res Clin Haematol
. 2007 Dec;
20(4):761-81.
PMID: 18070718
This chapter gives an account of the experience of the Arkansas myeloma program since 1989 with transplant-supported high-dose melphalan, novel agents, and prognostic factors as they relate to standard laboratory...
8.
Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, et al.
J Immunother
. 2007 Dec;
30(8):847-54.
PMID: 18049337
MAGE-A3 is frequently expressed in high-risk multiple myeloma (MM). We immunized a healthy donor with MAGE-A3 protein formulated in AS02B to transfer immunity to her identical twin, diagnosed with MAGE-A3-positive...
9.
Prasad H, Zhan F, Shaughnessy J
N Engl J Med
. 2007 Sep;
357(10):1048.
PMID: 17804853
No abstract available.
10.
Matsui S, Zeng S, Yamanaka T, Shaughnessy J
Biometrics
. 2007 Aug;
64(1):217-26.
PMID: 17680829
We develop formulae to calculate sample sizes for ranking and selection of differentially expressed genes among different clinical subtypes or prognostic classes of disease in genome-wide screening studies with microarrays....